Based on market analysis agency PharmaTrac, gross sales of anti-infectives rose to ₹2,359 crore in July 2026 from ₹2,107 crore in June, whereas these of antibacterials elevated to ₹2,109 crore from ₹1,883 crore. Gross sales of each the segments have been up 6% from July 2025.
Gastrointestinal medication gross sales rose about 1.8% to ₹2,081 crore in July from ₹2,045 crore in June, reflecting a seasonal rise in waterborne and digestive sicknesses, PharmaTrac information confirmed. “Sure therapies like antibacterials, cough and chilly might have illness seasonality patterns,” mentioned Sheetal Sapale, vice chairman, business, at PharmaTrac. Anti-infective medicines embrace antivirals and antibacterials, or antibiotics, amongst others.
With H1N1 circumstances recording a greater than sixfold improve in comparison with earlier years and the same old monsoon fevers together with dengue, typhoid, malaria and chikungunya already at seasonal highs, the demand for flu vaccines has additionally shot up. .
Manisha Mishra, vice chairman and lead, specialty pharma, at Tata 1mg, advised ET that gross sales in August have been almost 3 times increased than a 12 months earlier and greater than doubled from July, main to produce constraints in a number of cities.
